DASARI A , SHEN C , HALPERIN D , et al . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States [J ] . JAMA Oncol , 2017 , 3 ( 10 ): 1335 - 1342 . DOI: 10.1001/jamaoncol.2017.0589 http://doi.org/10.1001/jamaoncol.2017.0589

WHO Classification of Tumours Editorial Board . WHO classification of tumours of digestive system [M ] . Lyon : IARC Press , 2019 .

WHO Classification of Tumours Editorial Board . Thoracic tumours [M ] . 5th ed. International Agency for Research on Cancer , Lyon, France , 2021 .

CAPLIN M E , PAVEL M , ĆWIKŁA J B , et al . Lanreotide in metastatic enteropancreatic neuroendocrine tumors [J ] . N Engl J Med , 2014 , 371 ( 3 ): 224 - 233 . DOI: 10.1056/NEJMoa1316158 http://doi.org/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158

CAPLIN M E , PAVEL M , PHAN A T , et al . Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study [J ] . Endocrine , 2021 , 71 ( 2 ): 502 - 513 . DOI: 10.1007/s12020-020-02475-2 http://doi.org/10.1007/s12020-020-02475-2

JIMENEZ-FONSECA P , CARMONA-BAYONAS A , LAMARCA A , et al . External validity of somatostatin analogs trials in advanced neuroendocrine neoplasms: the GETNE-TRASGU study [J ] . Neuroendocrinology , 2022 , 112 ( 1 ): 88 - 100 . DOI: 10.1159/000514808 http://doi.org/10.1159/000514808 https://www.karger.com/Article/FullText/514808 https://www.karger.com/Article/FullText/514808

BAUDIN E , HORSCH D , SINGH S , et al . Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase Ⅲ SPINET study [J ] . Ann Oncol , 2021 , 32 : S906 . DOI: 10.1016/j.annonc.2021.08.178 http://doi.org/10.1016/j.annonc.2021.08.178 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023929 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023929

PAVEL M , ĆWIKŁA J B , LOMBARD-BOHAS C , et al . Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results [J ] . Eur J Cancer , 2021 , 157 : 403 - 414 . DOI: 10.1016/j.ejca.2021.06.056 http://doi.org/10.1016/j.ejca.2021.06.056

LEPAGE C , DAHAN L , BOUARIOUA N , et al . Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours [J ] . Dig Liver Dis , 2017 , 49 ( 5 ): 568 - 571 . DOI: 10.1016/j.dld.2017.02.004 http://doi.org/10.1016/j.dld.2017.02.004 https://linkinghub.elsevier.com/retrieve/pii/S1590865817302050 https://linkinghub.elsevier.com/retrieve/pii/S1590865817302050

LEPAGE C , PHELIP J M , LIÈVRE A , et al . Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): an international double-blind, placebo-controlled randomized phase Ⅱ trial [J ] . Ann Oncol , 2020 , 31 : S774 .

LIU Y M , LIU H K , CHEN W C , et al . Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden [J ] . Cancer Med , 2022 , 11 ( 13 ): 2588 - 2600 . DOI: 10.1002/cam4.4628 http://doi.org/10.1002/cam4.4628 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4628 https://onlinelibrary.wiley.com/doi/10.1002/cam4.4628

FEROLLA P , BRIZZI M P , MEYER T , et al . Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial [J ] . Lancet Oncol , 2017 , 18 ( 12 ): 1652 - 1664 . DOI: S1470-2045(17)30681-2 http://doi.org/S1470-2045(17)30681-2

PAVEL M E , HAINSWORTH J D , BAUDIN E , et al . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study [J ] . Lancet , 2011 , 378 ( 9808 ): 2005 - 2012 . DOI: S0140-6736(11)61742-X http://doi.org/S0140-6736(11)61742-X

RAYMOND E , DAHAN L , RAOUL J L , et al . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors [J ] . N Engl J Med , 2011 , 364 ( 6 ): 501 - 513 . DOI: 10.1056/NEJMoa1003825 http://doi.org/10.1056/NEJMoa1003825 http://www.nejm.org/doi/abs/10.1056/NEJMoa1003825 http://www.nejm.org/doi/abs/10.1056/NEJMoa1003825

XU J M , SHEN L , BAI C M , et al . Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study [J ] . Lancet Oncol , 2020 , 21 ( 11 ): 1489 - 1499 . DOI: 10.1016/S1470-2045(20)30493-9 http://doi.org/10.1016/S1470-2045(20)30493-9

LI J , XU J , ZHOU Z , et al . Safety profile and adverse events of special interest for surufatinib in chinese patients with advanced extra-pancreatic neuroendocrine tumors: analysis of the phase 3 SANET-ep trial [J ] . Lung , 2020 , 37 : 4585 - 4598 .

CAPDEVILA J , FAZIO N , LOPEZ LOPEZ C , et al . Final results of the TALENT trial (GETNE1509): a prospective multicohort phase Ⅱ study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs) [J ] . J Clin Oncol , 2019 , 37 (15_suppl): 4106.

CAPDEVILA J , JIMENEZ-VALERIO G , MARTINEZ A , et al . Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: results from the international phase Ⅱ TALENT trial (GETNE 1509) [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 4113 . DOI: 10.1200/JCO.2021.39.15_suppl.4113 http://doi.org/10.1200/JCO.2021.39.15_suppl.4113 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4113 https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4113

STROSBERG J R , CIVES M , HWANG J , et al . A phase Ⅱ study of axitinib in advanced neuroendocrine tumors [J ] . Endocr Relat Cancer , 2016 , 23 ( 5 ): 411 - 418 . DOI: 10.1530/ERC-16-0008 http://doi.org/10.1530/ERC-16-0008 https://erc.bioscientifica.com/view/journals/erc/23/5/411.xml https://erc.bioscientifica.com/view/journals/erc/23/5/411.xml

LEVY S , VERBEEK W H M , ESKENS F A L M , et al . First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial [J ] . Ther Adv Med Oncol , 2022 , 14 : 17588359221077088.

中国抗癌协会神经内分泌肿瘤专业委员会 . 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版) [J ] . 中国癌症杂志 , 2022 ( 6 ): 545 - 580 .

Society of Neuroendocrine Neoplasm of China Anti-Cancer Association . China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition) [J ] . China Oncol , 2022 ( 6 ): 545 - 580 .

GIROT P , BAUDIN E , SENELLART H , et al . Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the French group of endocrine tumors [J ] . Neuroendocrinology , 2022 , 112 ( 6 ): 537 - 546 . DOI: 10.1159/000518650 http://doi.org/10.1159/000518650 https://www.karger.com/Article/FullText/518650 https://www.karger.com/Article/FullText/518650

BUTT B P , STOKMO H L , LADEKARL M , et al . Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas [J ] . Ann Oncol , 2021 , 32 : S915 .

ACOMBE C , PERRIER M , HENTIC O , et al . FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors [J ] . Ann Oncol , 2021 , 32 (suppl_5): S621-S625.

MEHNERT J M , BERGSLAND E , O’NEIL B H , et al . Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study [J ] . Cancer , 2020 , 126 ( 13 ): 3021 - 3030 . DOI: 10.1002/cncr.32883 http://doi.org/10.1002/cncr.32883

STROSBERG J , MIZUNO N , DOI T , et al . Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study [J ] . Clin Cancer Res , 2020 , 26 ( 9 ): 2124 - 2130 . DOI: 10.1158/1078-0432.CCR-19-3014 http://doi.org/10.1158/1078-0432.CCR-19-3014 https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously https://aacrjournals.org/clincancerres/article/26/9/2124/83112/Efficacy-and-Safety-of-Pembrolizumab-in-Previously

LU M , ZHANG P P , ZHANG Y Q , et al . Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase ib trial [J ] . Clin Cancer Res , 2020 , 26 ( 10 ): 2337 - 2345 . DOI: 10.1158/1078-0432.CCR-19-4000 http://doi.org/10.1158/1078-0432.CCR-19-4000

PATEL S P , OTHUS M , CHAE Y K , et al . A phase Ⅱ basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors [J ] . Clin Cancer Res , 2020 , 26 ( 10 ): 2290 - 2296 . DOI: 10.1158/1078-0432.CCR-19-3356 http://doi.org/10.1158/1078-0432.CCR-19-3356 https://aacrjournals.org/clincancerres/article/26/10/2290/82362/A-Phase-II-Basket-Trial-of-Dual-Anti-CTLA-4-and https://aacrjournals.org/clincancerres/article/26/10/2290/82362/A-Phase-II-Basket-Trial-of-Dual-Anti-CTLA-4-and

Thoracique IFdC , Digestive FFdC , Group G-MOC (2019) Nivolumab +/- ipilimumab in patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) [EB/OL ] . ( 2020 - 10 - 09 )[ 2022 - 08 - 25 ] . https://clinicaltrials.gov/show/NCT03591731 https://clinicaltrials.gov/show/NCT03591731 https://clinicaltrials.gov/show/NCT03591731 .

CAPDEVILA J , TEULE A , LÓPEZ C , et al . A multi-cohort phase Ⅱ study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: the DUNE trial (GETNE 1601) [J ] . Ann Oncol , 2020 , 31 : S770-S771.

HORN L , MANSFIELD A S , SZCZĘSNA A , et al . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 23 ): 2220 - 2229 . DOI: 10.1056/NEJMoa1809064 http://doi.org/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064 http://www.nejm.org/doi/10.1056/NEJMoa1809064

PAZ-ARES L , DVORKIN M , CHEN Y B , et al . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J ] . Lancet , 2019 , 394 ( 10212 ): 1929 - 1939 . DOI: 10.1016/S0140-6736(19)32222-6 http://doi.org/10.1016/S0140-6736(19)32222-6 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226 https://linkinghub.elsevier.com/retrieve/pii/S0140673619322226

RIESCO-MARTINEZ M C , CAPDEVILA J , ALONSO V , et al . Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: preliminary results from the phase Ⅱ NICE-NEC trial (GETNE T1913) [J ] . Ann Oncol , 2021 , 32 : S908 - S909 . DOI: 10.1016/j.annonc.2021.08.180 http://doi.org/10.1016/j.annonc.2021.08.180 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023942 https://linkinghub.elsevier.com/retrieve/pii/S0923753421023942

HALPERIN D M , LIU S Y , DASARI A , et al . Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial [J ] . JAMA Oncol , 2022 , 8 ( 6 ): 904 - 909 . DOI: 10.1001/jamaoncol.2022.0212 http://doi.org/10.1001/jamaoncol.2022.0212

CAO Y S , LU M , SUN Y , et al . Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial [J ] . J Cancer Res Clin Oncol , 2022 . Online ahead of print.

WHALEN K A , WHITE B H , QUINN J M , et al . Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: a potent and novel therapeutic for the treatment of small cell lung cancer [J ] . Mol Cancer Ther , 2019 , 18 ( 11 ): 1926 - 1936 . DOI: 10.1158/1535-7163.MCT-19-0022 http://doi.org/10.1158/1535-7163.MCT-19-0022

SAUNDERS L R , BANKOVICH A J , ANDERSON W C , et al . A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo [J ] . Sci Transl Med , 2015 , 7 ( 302 ): 302 ra136.

DENG S M , YAN X C , LIANG L , et al . The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice [J ] . Biochem Biophys Res Commun , 2017 , 483 ( 1 ): 488 - 494 . DOI: 10.1016/j.bbrc.2016.12.117 http://doi.org/10.1016/j.bbrc.2016.12.117 https://linkinghub.elsevier.com/retrieve/pii/S0006291X16321775 https://linkinghub.elsevier.com/retrieve/pii/S0006291X16321775

HERMANS B C M , DERKS J L , THUNNISSEN E , et al . DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile [J ] . Lung Cancer , 2019 , 138 : 102 - 108 . DOI: S0169-5002(19)30680-4 http://doi.org/S0169-5002(19)30680-4

MATSUO K , TANIGUCHI K , HAMAMOTO H , et al . Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy [J ] . Cancer Sci , 2019 , 110 ( 10 ): 3122 - 3131 . DOI: 10.1111/cas.14157 http://doi.org/10.1111/cas.14157 https://onlinelibrary.wiley.com/doi/10.1111/cas.14157 https://onlinelibrary.wiley.com/doi/10.1111/cas.14157

RUDIN C M , PIETANZA M C , BAUER T M , et al . Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study [J ] . Lancet Oncol , 2017 , 18 ( 1 ): 42 - 51 . DOI: S1470-2045(16)30565-4 http://doi.org/S1470-2045(16)30565-4

MORGENSZTERN D , BESSE B , GREILLIER L , et al . Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase Ⅱ TRINITY study [J ] . Clin Cancer Res , 2019 , 25 ( 23 ): 6958 - 6966 . DOI: 10.1158/1078-0432.CCR-19-1133 http://doi.org/10.1158/1078-0432.CCR-19-1133 https://aacrjournals.org/clincancerres/article/25/23/6958/82239/Efficacy-and-Safety-of-Rovalpituzumab-Tesirine-in https://aacrjournals.org/clincancerres/article/25/23/6958/82239/Efficacy-and-Safety-of-Rovalpituzumab-Tesirine-in

MORGENSZTERN D , JOHNSON M , RUDIN C M , et al . SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study [J ] . Lung Cancer , 2020 , 145 : 126 - 131 . DOI: S0169-5002(20)30387-1 http://doi.org/S0169-5002(20)30387-1

MIYAGAWA-HAYASHINO A , OKADA S , TAKEDA-MIYATA N , et al . TTF-1 and c-MYC-defined phenotypes of large cell neuroendocrine carcinoma and delta-like protein 3 expression for treatment selection [J ] . Appl Immunohistochem Mol Morphol , 2021 , 29 ( 4 ): 313 - 320 . DOI: 10.1097/PAI.0000000000000875 http://doi.org/10.1097/PAI.0000000000000875 https://journals.lww.com/10.1097/PAI.0000000000000875 https://journals.lww.com/10.1097/PAI.0000000000000875

THOMAS A , TAKAHASHI N , RAJAPAKSE V N , et al . Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress [J ] . Cancer Cell , 2021 , 39 ( 4 ): 566 - 579 .e7. DOI: 10.1016/j.ccell.2021.02.014 http://doi.org/10.1016/j.ccell.2021.02.014

JONASCH E , DONSKOV F , ILIOPOULOS O , et al . Belzutifan for renal cell carcinoma in von hippel-lindau disease [J ] . N Engl J Med , 2021 , 385 ( 22 ): 2036 - 2046 . DOI: 10.1056/NEJMoa2103425 http://doi.org/10.1056/NEJMoa2103425 http://www.nejm.org/doi/10.1056/NEJMoa2103425 http://www.nejm.org/doi/10.1056/NEJMoa2103425

KLEMPNER S J , GERSHENHORN B , TRAN P , et al . BRAF V600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy [J ] . Cancer Discov , 2016 , 6 ( 6 ): 594 - 600 . DOI: 10.1158/2159-8290.CD-15-1192 http://doi.org/10.1158/2159-8290.CD-15-1192

IDREES K , PADMANABHAN C , LIU E , et al . Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma [J ] . J Surg Oncol , 2018 , 117 ( 2 ): 284 - 289 . DOI: 10.1002/jso.24834 http://doi.org/10.1002/jso.24834 https://onlinelibrary.wiley.com/doi/10.1002/jso.24834 https://onlinelibrary.wiley.com/doi/10.1002/jso.24834

CAPDEVILA J , ARQUÉS O , HERNÁNDEZ MORA J R , et al . Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAF V600E blockade in col on neuroendocrine carcinomas [J ] . Clin Cancer Res , 2020 , 26 ( 4 ): 902 - 909 . DOI: 10.1158/1078-0432.CCR-19-1266 http://doi.org/10.1158/1078-0432.CCR-19-1266 https://aacrjournals.org/clincancerres/article/26/4/902/83196/Epigenetic-EGFR-Gene-Repression-Confers https://aacrjournals.org/clincancerres/article/26/4/902/83196/Epigenetic-EGFR-Gene-Repression-Confers

BURKART J , OWEN D , SHAH M H , et al . Targeting BRAF mutations in high-grade neuroendocrine carcinoma of the colon [J ] . J Natl Compr Canc Netw , 2018 , 16 ( 9 ): 1035 - 1040 . DOI: 10.6004/jnccn.2018.7043 http://doi.org/10.6004/jnccn.2018.7043 https://jnccn.org/doi/10.6004/jnccn.2018.7043 https://jnccn.org/doi/10.6004/jnccn.2018.7043